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esponsibility of InstAbstract Dry powder inhalers (DPIs) offer distinct advantages as a means of pulmonary drug delivery
and have attracted much attention in the ﬁeld of pharmaceutical science. DPIs commonly contain
micronized drug particles which, because of their cohesiveness and strong propensity to aggregate, have
poor aerosolization performance. Thus carriers with a larger particle size are added to address this
problem. However, the performance of DPIs is profoundly inﬂuenced by the physical properties of the
carrier, particularly their particle size, morphology/shape and surface roughness. Because these factors are
interdependent, it is difﬁcult to completely understand how they individually inﬂuence DPI performance.
The purpose of this review is to summarize and illuminate how these factors affect drug–carrier interaction
and inﬂuence the performance of DPIs.
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Figure 1 Two methods of combining drug and carrier for use in dry
powder inhalers.
Inﬂuence of carrier on dry powder inhalers 3091. Introduction
With increases in our understanding of the physiology of the lung
and related diseases, pulmonary drug delivery (PDD) is becoming
an alternative choice to treat local and systemic diseases. PDD
systems take a variety of forms ranging from nebulizers to
inhalers1 and deliver drug directly to the site of action in the lung
or to a distant site via the bloodstream. PDD possesses several
distinct advantages. First, due to the high permeability, large
surface area (about 100 m2) and thin adsorption membrane
(0.1–0.2 mm) of the lung, and because of its excellent blood
supply (5 L/min), inhalation produces rapid systemic onset almost
comparable to intravenous injection2. Secondly, because the lung
exhibits relatively low metabolic activity, drugs delivered via the
lung are not susceptible to ﬁrst pass metabolism making the lung
an attractive administration route for proteins and peptides3.
For these reasons, PDD is highly desirable for the treatment of
patients with pulmonary diseases such as pneumonia, asthma,
cystic ﬁbrosis, chronic obstructive pulmonary disease and lung
cancer.
PDD systems can be divided into three major categories viz
nebulizers, pressurized metered-dose inhalers (pMDIs) and dry
powder inhalers (DPIs). Nebulizers, the ﬁrst type of device
developed for inhalation therapy, utilize an air jet or ultrasound
to convert a drug solution or suspension into ﬁne droplets which
are then inhaled by the patient over a couple of minutes4.
However, nebulizers are not portable, suffer from poor reprodu-
cibility in delivering an accurate dose and are only commonly used
in hospitals. Since the 1950s, portable pMDIs have been devel-
oped and have become the mainstay of asthma therapy with good
patient compliance. Nevertheless, they require good coordination
between actuation and inhalation and only a small fraction of drug
reaches the patient's lungs due to the high particle exit velocity.
They are also environmentally unfriendly because they require a
chloroﬂuorocarbon propellant that depletes the ozone layer. In
contrast, the DPI is propellant-free, portable, easy to operate, low-
cost, and provides better formulation stability than liquid dosage
forms. In particular, the development of DPIs was stimulated by
the Montreal Protocol (1987) which recommended the removal of
chloroﬂuorocarbon propellants5,6.
DPIs consist of an active pharmaceutical ingredient (API) of
suitable aerodynamic size (usually 1–5 mm) for inhalation7, con-
tained within a device which, upon inhalation, provides sufﬁcient
deagglomeration of particles to deliver a therapeutic dose to the
lungs. The main problem with particles of this small micron size is
that their high surface free energy makes them stick to each other
(via cohesive forces) or to any surface they encounter (via
adhesive forces). As a result, they exhibit poor ﬂowability and
aerosolization performance and have a propensity to remain within
the inhaler. In addition, many APIs used for treating local diseases
such as asthma are highly potent and require only a low dose
(200–400 mg for salbutamol and 6–12 mg for formoterol)8 which
poses signiﬁcant problems in relation to powder handling and
accurate metering of doses. Recently, a DPI containing carrier
particles as well as drug has been developed to overcome these
limitations. The functions of the carrier include (1) improving
ﬂowability of drug particles to facilitate ﬁlling the DPI, (2) increas-
ing dispersion of drug particles during emission and (3) diluting
the drug to improve accurate dose delivery7.
Aerodynamic diameter (dae) is the best parameter to evaluate
the ability of ﬁne drug particles to deposit deep within the lung. It
is deﬁned (Eq. (1)) as the diameter of spherical particles of unitdensity that reach the same terminal velocity and deposition as the
particles under investigation9:
daeﬃdg
ﬃﬃﬃﬃﬃﬃﬃ
ρp
ρ0χ
r
ð1Þ
where dg is the geometric diameter of the spherical particle, ρp and
ρ0 represent the particle density and unit density respectively and χ
is the shape factor.
This equation indicates that dae is inﬂuenced by particle size,
morphology/shape and density. For porous particles with low
density, dae≪dg10, and particle size has a greater effect on drug
deposition than particle density. Since the amount of API in a DPI
is relatively low (0.05%–10%)11, a slight change in the physical
properties of the carrier has a considerable effect on DPI
performance. It was also reported that carrier surface properties
(e.g., surface area, morphology and roughness) play a signiﬁcant
role in determining interparticulate interactions, stability, ease of
dispersion, and de-agglomeration12. Therefore, considerable
researches have focused on particle characteristics of carriers to
investigate their inﬂuence on the performance of DPIs. These
important carrier characteristics are discussed below.2. Approaches to produce DPI formulations
As shown in Fig. 1, there are commonly two approaches to produce
a DPI formulation. One approach is to dissolve drug and carrier in a
solvent and then remove solvent by spray drying or other methods
(Fig. 1A). The size of the resulting particles is in the range 1–5 mm
which, on inhalation, ensures the drug is deposited deep in the
lung. The second approach is to combine drug and carrier via
particle interactions (Fig. 1B) so that, on inhalation, drug is carried
past the respiratory tree and released deep in the lung. Carriers used
are commonly coarse particles with a size range of 50–200 mm13
which are designed to be swallowed after impact with the upper
respiratory tract14 so that only ﬁne drug particles are deposited deep
in the lung. Due to the lack of toxicological data concerning the
potential hazard of carriers to lung tissue, the number of carrier
materials currently approved or certiﬁed safe by the U.S. Food and
Drug Administration (FDA) remains limited so much so that most
commercially available DPI formulations rely on lactose as the
carrier15. Therefore, DPIs in which the API is physically combined
with carrier are superior in reducing lung deposition and adverse
effects of the carrier while retaining lung deposition of drug.
Section 3 focuses on such physically combined DPI formulations.
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In the development of a DPI formulation, two types of inter-
particulate interaction should be taken into consideration viz the
drug–drug cohesive force and the drug–carrier adhesive force16.
The drug–carrier adhesive force fundamentally determines the
performance of a DPI since excessive adhesion limits drug
detachment from the carrier during aerosolization leading to poor
drug dispersion17. Generally, the adhesion of a micron-sized
particle to a solid surface is governed by physical forces (Fig. 2)
including the van der Waals force18, interlocking force19, electro-
static force20 and capillary force21.
Under conditions where particles can dissipate excess electric
charge and humidity is controlled, the van der Waals force is the
dominant interaction and creates a so-called ‘‘Velcro effect’’
between particles20,22. The interlocking force is involved when
drug particles ﬁt into cavities upon intimate contact with the carrier
surface23. The electrostatic force occurs when two materials with
different surface charge come into contact and then separate23,24.
The capillary force is developed due to the formation of a liquid
bridge between particles which is inﬂuenced by the surrounding
relative humidity and varies with the type of drug used in the
formulation21,25,26.
Overall, the contribution of these forces to particle adhesion is
dependent on environmental conditions and several factors related
to the particle such as its surface physical properties, mechanical
properties27, area, size and solid-state nature26. Because the
performance of a DPI formulation depends on dissociation of
drug from carrier particles and deaggregation of drug agglomeratesFigure 2 Physical interparticulate forces between the drug and
carrier.
Figure 3 Mechanisms of aerosol generation and deposiduring aerosolization, any factor that affects the drug–carrier
interaction may also affect drug delivery and deposition28. To
ensure an inhaled formulation is therapeutically effective, the
interactions should be strong enough to ensure homogeneity and
stability during powder handling but sufﬁciently weak to allow the
formulation to be readily dispersed18,29. It is worth noting that the
dispersion of a drug–carrier mixture is greatly inﬂuenced by the air
velocity, the higher the airﬂow the greater the detachment of API
particles from the carrier30.
Several formulation approaches have been applied to improve
the aerosolization performance of drug–carrier adhesive mixtures.
They generally focus on minimizing the intrinsic cohesion of the
powder and/or reducing the interaction between drug and carrier.
Speciﬁcally, the approaches include particle size reﬁnement16,
morphology design31 and surface modiﬁcation32.4. Mechanisms of aerosol generation and deposition
Unlike oral dosage forms, the efﬁciency of a DPI principally
depends on the extent to which the drug particles in the
formulation can be dispersed into an aerosol during inhalation33.
Only free particles in the inhalatory airstream that have overcome
the interparticulate forces within the bulk powder can be delivered
deep into the lung. Therefore, one of the main challenges in the
inhalation ﬁeld is to reproducibly deliver the highest dose fraction
of drug to the lung. Until now, most research into the development
of DPIs has focused on improving the ﬁne particle fraction (FPF)
to generate an efﬁcient aerosol by particle engineering of the
carrier. FPF denotes the percentage relative to the total quantity of
drug collected in the impactor or impinger that has a size r5 μm.
The higher the FPF the better the aerosolization efﬁciency. FPF is
inﬂuenced by the inhalation device34, formulation35,36 (character-
istics and downstream processability of the carrier, drug to carrier
ratio), and in vitro characteristics of the aerosol37 (delivery time
and rate of delivery).
However, the mechanism of aerosol generation by a DPI
remains complex. The scheme of airway geometry shown in
Fig. 3 indicates that the airway can be divided into two distinct
zones viz the conducting zone and the respiratory zone38. The
conducting zone consists of the ﬁrst 16 generations beginning withtion of drug in the airways for a dry powder inhaler.
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(generation 16). Its main function is to allow the bulk ﬂow of air to
move into and out of the lung during each breath. The respiratory
zone is where gas exchange occurs. It starts at the respiratory
bronchioles (generation 17) and terminates at the alveolar sacs
(generation 23). In moving from trachea to alveolar sacs, there are
two pronounced physical changes along the airways; the airway
caliber decreases and the cross-sectional area of the airways
increases as the number of airways increases12. These changes
lead to variations in air ﬂow velocity and airway surface area
which have signiﬁcant effects on drug deposition in the lung.
According to Hickey et al.39, the aerosolization process can be
roughly divided into four consecutive phases: detachment from the
static powder bed, ﬂuidization, entrainment and drug resuspension
(Fig. 3). The powder bed remains static until the airﬂow generated
by the DPI device transfers kinetic energy into the bed causing
powder deaggregation. Powder ﬂuidization is the process in which
the powder mass disturbed by the airstream exhibits “ﬂuid-like”
properties40. It is primarily governed by the packing properties of
the powder which are closely related to the physical properties of
the particles and their interfacial interactions41. Following ﬂuidiza-
tion, the powder is entrained into the airﬂow42, and these two
processes are critical in the ability of a DPI to generate a
therapeutically effective aerosol. Drug resuspension is mainly
performed by deagglomeration forces including turbulent, inertial
and impacting stresses and is followed by deposition of drug in the
respiratory tract39.
Typically, there are three mechanisms (Fig. 3) governing particle
deposition in lung airways. (1) Inertial impaction: this involves
inertial deposition of particles onto the airway surfaces and mainly
occurs close to bifurcations of the large conducting airways43. Most
large particles (46 μm) are deposited in the oropharyngeal and
large airways because they are unable to follow the directional
changes of the inspired airstream particularly in the oropharynx and
at airway bifurcations. Thus loss of drug due to inertial impaction
in the oropharynx is the major hurdle to achieve lung deposition
using a passive dry powder device44. (2) Gravitational sedimenta-
tion: this usually involves small particles in the size range 2–6 mm
and occurs in the small conducting airways where the airﬂowFigure 4 Concurrent changes of powder ﬂuidization and aerosovelocity is slow12. (3) Diffusion: this involves small particles
(o2 mm) for which Brownian motion is important and occurs in
the small airways and alveoli where the airﬂow is negligible12.
Overall, aerosol generation results from a competition between
interparticulate interactions within the adhesive mixture and
separation forces resulting from the inspiratory airﬂow through
the inhaler.5. Inﬂuence of carrier characteristics on aerosol
performance
5.1. Particle size
It is well recognized that particle size of the carrier plays a
dominant role in the aerosolization performance of carrier-based
DPI formulations. However, there is, as yet, no consensus on how
carrier particle size affects DPI performance. One study reported
that reducing particle size improves the amount of respirable drug
delivered from a DPI16 but has adverse effect on drug content
uniformity and results in more drug deposited in the oropharyngeal
region16. Interestingly, carrier particle size does not necessarily
impact negatively on drug deposition after inhalation and in
another study a higher FPF was observed45. These conﬂicting
results could be due to the interdependence of physical properties.
Whatever the case, particle size must be optimized to provide
efﬁcient aerosolization and overcome the disadvantages of small
particles.
To establish the optimum particle size of aerosols, it is
important to take into account the physical properties of carrier
particles including their shape, surface roughness, density and
geometric diameter43. The effect of these variables on aerosol
performance has been studied by Ooi et al.46 using three model
polystyrene spheres with d0.5 values of 82.8, 277.5 and 582.9 μm
as carriers. The results showed that aerosol performance increased
as particle size decreased, a ﬁnding ascribed to the decreasing
particle size, including decreased number of drug particles per
carrier and the increases in particle number, surface area, inter-
carrier adhesion and number of collisions in the powder bed duringlization as a function of particle size (↑ increase, ↓ decrease).
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by the number of frictional and rotational collisions rather than
conventional momentum transfer.
5.1.1. Particle size distribution
Particle size distribution is important in terms of aerosol quality
and efﬁciency47. It is commonly evaluated by determining poly-
dispersibility (PDI) which is calculated according to Eq. (2). A
larger value of PDI of the carrier indicates a wider particle size
distribution, and produces a more heterogeneous mixture with
drug. This may lead to higher variability in lung deposition of drug
upon inhalation16.
PDI¼ d90d10
d50
ð2Þ
Measurement of particle size and particle size distribution can
be conducted using sieving, optical microscopy, and laser diffrac-
tion particle size analyzer. Sieving is considered to be a rough
method in determining particle size because it does not give exact
measurements of any dimension of the particles48. Microscope
image analysis is used for umber-weighted size measurement,
while laser diffraction volume is used for weighted size measure-
ment. On the other hand, the accuracy of size measurement by
laser diffraction is affected by the particle shape and surface
properties. Particles with irregular shape and rough surface
morphology may lead to “overestimated” size measurements, as
observed by Kaialy et al.49.
5.1.2. Role of ﬁne carrier particles
The inclusion of a small amount of ﬁne carrier particles (ﬁnes) in a
DPI formulation is a well-researched technique to improve DPI
performance. The actual deﬁnition of ﬁnes is unclear in the
literature but there is agreement that ﬁnes have a small particleFigure 5 Theories and hypothesis describing the effect of ﬁne carrier pa
“Active sites theory”; (B) “agglomeration theory”; (C) “ﬂuidization theorysize compared to coarse particles10,13,23. It has also been suggested
that ﬁnes with similar geometric size to that of the API should be
used50. However, the optimum diameter of ﬁnes for use in a DPI
formulation has not reached a consencus51.
There have been numerous studies investigating how ﬁnes affect
the performance of DPI formulations with contradictory results.
Some studies showed that a small quantity of ﬁnes included in a
powder formulation could increase the deaggregation efﬁciency and
therefore the therapeutic efﬁcacy of the DPI52,53. However,
Hamishehkar et al.54 demonstrated that the addition of ﬁnes with
spray dried mannitol and leucine decreased both the deposition and
dispersibility of microcapsules. Steckel et al.55 also reported that the
presence of ﬁnes caused a decrease in FPF. Several hypotheses to
explain how the presence of ﬁnes affects the aerosolization
performance of a DPI have been proposed based on studies of
lactose ﬁnes. These include the active-sites56, agglomeration52 and
ﬂuidization theories57, the buffer hypothesis58 and case-dependent59
theory. With the exception of case-dependent theory, these theories
address the positive effects of ﬁnes on the dispersion performance of
adhesive mixtures. However, the long-term safety of excipients for
use as ﬁnes remains to be established and is a matter of concern to
regulatory authorities51. For example, ﬁnes may cause irritation,
coughing and even bronchoconstriction60 and in the case of inhaled
mannitol can increase bronchial hyperresponsiveness61.
5.1.2.1. Active-sites theory. This was ﬁrst introduced by Her-
sey62 and subsequently widely applied to understand the behavior
of adhesive mixtures. The so-called “active sites”, deﬁned as areas
on the carrier surface that are more adhesive than others (Fig. 5A),
are preferentially occupied by ﬁnes leaving the weaker binding
sites to be occupied by drug particles23,59. However, Grasmeijer
et al.63 pointed out that a speciﬁc deﬁnition of “active sites” has
never been established and that the theory is ambiguous inrticles on the aerosolization performance of a dry powder inhaler: (A)
” and (D) “buffer hypothesis” (modiﬁed from Refs. 47 and 48.
Figure 6 Scanning electron microscopy images of (A) large CL, (B) small CL, (C) large PL, (D) small PL, (E) large NL, and (F) small NL carrier
particles (reproduced from Ref. 65 with permission).
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inhalation. As a result, “active sites” have been newly deﬁned
based on their ability to retain drug during dispersion which
depends on the physical properties of the carrier surface, formula-
tion and dispersion conditions. A rational choice of such condi-
tions is of utmost importance in studies concerning carrier surface
site activity.
5.1.2.2. Agglomeration theory. According to this theory and as
shown in Fig. 5B, the improved DPI performance due to the
presence of ﬁnes results from the formation of drug-ﬁne agglom-
erates. These are more likely to be removed from the carrier
particle surface than free API particles due to the greater
aerodynamic drag force acting on agglomerates64.
5.1.2.3. Fluidization theory. As illustrated in Fig. 5C, ﬂuidiza-
tion of a DPI formulation occurs when the pressure drop across the
static powder bed is equivalent to the weight of the powder40. This
pressure threshold is referred to as the point of incipient ﬂuidiza-
tion or minimum ﬂuidization velocity (MFV)42. The addition of
ﬁnes improves DPI performance by increasing the tensile strength
of the formulation which is directly related to interparticulate
forces and the free volume of the carrier. This signiﬁcantly shifts
the MFV and thereby increases the aerodynamic drag force exerted
to ﬂuidize the powder bed57.
5.1.2.4. Buffer hypothesis. The commercially available brands of
alpha-lactose monohydrate normally exhibit surface rugosity
and carry natural ﬁnes and impurities on their surface which
may inﬂuence their interaction with drug in adhesive mixtures
for inhalation. In a study involving submerging lactose in
ethanol–water mixtures, Dickhoff et al.58 found that submersion
removed the adhering lactose ﬁnes leading to a decrease in drug
particle detachment without affecting the shape or size of carrier
particles. This is the basis of the buffer hypothesis (Fig. 5D) which
states that the adhering lactose ﬁnes act as a buffer betweencolliding carrier particles and protect smaller drug particles
attached to the same crystal planes from the press-on forces that
cause increased drug particle detachment during inhalation58.
5.1.2.5. Case-dependent theory. Contrary to the mechanisms
described above, Grasmeijer et al.59 pointed out that ﬁnes do not
always improve the aerosol performance of a DPI which is
determined by the formulation and dispersion conditions. They
studied the effects of “ﬁne lactose ﬁnes” (FLF) with similar size
and shape as micronised budesonide on drug detachment and
compared the results with those obtained using “coarse lactose
ﬁnes” (CLF) at varying inhalation ﬂow rates, drug contents and
mixing orders. It was found that the presence of CLF resulted in
higher detachment of drug at all ﬂow rates and drug contents and
the effects of FLF were negligible at high drug content. These
results implicate two new mechanisms. First, ﬁnes below a certain
size reduce dispersion performance probably by increasing the
effectiveness of press-on forces or the formation of coherent ﬁne
particle networks on the carrier surface. Secondly, the CLF may
weaken or prevent the formation of ﬁne particle networks possibly
through lowering tensile strength.5.2. Morphology/shape
The morphology/shape of carrier particles exerts a dominant effect
on the aerosolization performance of a DPI31. Particles with
different shapes may be subject to different drag forces and
terminal velocities during aerosolization which, in turn, affect
their deposition in the respiratory airways47.
The effect of particle shape on aerosolization performance has
been widely investigated. Kaialy et al.31 examined carriers with
different morphologies to investigate the effect of elongation ratio
(ER). They concluded that the higher the ER the greater the
delivery of salbutamol sulphate to the lower airway regions of the
lung, indicating enhanced DPI performance. However, this
Tingting Peng et al.314improvement was restricted to values below a certain “limit” since
the higher the ER the more the drug remained in the inhaler device
and deposited in the throat. Using lactose as a carrier, Kho et al.65
also investigated the effect of carrier particle shape in two size
ranges (i.e. 50–70 μm and 14–20 μm) (Fig. 6)65 on aerosolization
efﬁciency of drug–carrier particle blends containing amorphous
nanoparticles of drug. The results revealed that lactose particles of
tomahawk shape gave similar aerosolization efﬁciency to those
with needle and pollen shape for both large and small carrier
particles, a ﬁnding contrary to that of a previous study using drug
microparticles66–68. Needle shaped carrier particles generally have
a high ER which allows drug deposition in the small airways44
resulting in more effective drug deposition in the lung66. Pollen
shaped carrier particles with low density bind drug for longer
periods and thereby give higher lung deposition67,68. According to
Hassan et al.67, pollen-shaped carrier particles give a higher FPF
and reduce drug loss especially at low ﬂow rates and high drug
content. However, size and surface morphology of carrier particles
can have opposing effects as indicated by the fact that an increase
in particle size has a mild effect on emission dose (ED) but may
signiﬁcantly improve the FPF while a sparse surface has negligible
effect on the ED at low ﬂow rates but improves the FPF.
As shown in Table 17,16,28,31,69,70, shape analysis is commonly
conducted using scanning electron microscopy (SEM), optical
microscopy or some other imaging technique. The parameters used
to quantify particle shape include ER, ﬂatness ratio (FR), round-
ness (RO), shape factor (Fshape), angularity, and surface factor
(Fsurface).
ER and FR are considered to be ﬁrst order shape descriptors71.
ER is a measure of the irregularity of particles which reﬂects
overall particle shape elongation72. A higher value of ER indicatesTable 1 Shape descriptors and characterization methods to evaluate
Shape descriptor Order rank Equation D
Elongation ratio (ER) First ER¼ Lw O
Flatness ratio (FR) First FR¼ Lw O
Roundness (RO) — RO¼ p24πA O
Shape factor (Fshape) Second Fshape ¼ 4πAp O
Angularity Second Angularity¼ pconvexpellipse O
Surface factor (Fsurface) Third Fsurface ¼ Fshape  ð1þERÞ
2
πER
O
A, the estimated area of the particle;
Angularity, a parameter to quantify particle shape;
L, length, the maximum Feret diameter;
p, Perimeter, the estimated perimeter of particle with compensation for cor
Pconvex, perimeter of the minimum convex boundary circumscribing the pa
Pelipse, perimeter of ﬁctitious equivalent ellipse which has the same area an
w, width, the minimum Feret diameter;
—, there has been no rank order designated for RO.
Figure 7 Carrier particles with three different sizes of surface rough
topography (modiﬁed from Ref. 78).a more elongated/irregular shape and/or a rougher surface73 and
follows a similar trend as RO. Carrier particles with high ER and
RO values are likely to exhibit pronounced internal friction due to
their angular shape and are expected to produce different
aerosolization characteristics74,75. It has been reported that carrier
particles with high ER can signiﬁcantly increase the amount of
drug delivered to lower airway regions of the lung but only up to a
certain level. However, carrier particles with high ER are
disadvantageous in DPI dose metering and processing at handling
scale due to their poor ﬂowability31. A high FR is indicative of a
more ﬂattened shape7, while a high value of ER/FR is indicative of
a more elongated/less ﬂattened particle shape. Smooth spheres and
perfect cubes have ER and FR of 1.
Fshape and angularity are second order descriptors of particle shape
irregularity7,71. The value for Fshape ranges from 1 to 1 where a
smooth sphere has Fshape of 1
70 and a smaller Fshape value indicates
greater shape irregularity and/or rougher particle surface7. Particle
angularity is independent of particle ER76. However, values of Fshape
and ER alone may be insufﬁcient to describe the effect of particle
shape since these parameters are functions of particle orientation and
contact area only which can inﬂuence the accuracy of shape
assessment using microscopic image analysis70,77. SEM is also needed
to characterize qualitatively the three dimensional shape and surface
morphology of carrier particles.
Fsurface is a third order shape descriptor which refers to surface
roughness only7. Cubic particles with smooth surface are expected
to have Fsurface of 1, and a smaller Fsurface value indicates a rougher
surface.
Of these various shape descriptors of particles, ER is solely
determined by their macroscopic shape while rugosity and Fshape
are dependent on both macroscopic shape and surface texture.particle shape or morphology.
etermination method Ref.
ptical microscopy or scanning electron microscopy (SEM) 28,69
ptical microscopy 7
ptical microscopy 31
ptical microscopy 70
ptical microscopy 16
ptical microscopy 7
ners;
rticle;
d the aspect ratio of aggregate particle;
ness; (A) micrometer topography, (B) smooth, and (C) nanometer
Table 2 Characterization methods to determine surface roughness of carrier particles.
Characterization method Equation Result Ref.
Direct method Atomic force microscopy (AFM)
RRMS ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n
Pn
i ¼ 1
y2i ¼1
s
No signiﬁcance between the surface roughness of composite carriers and regular carriers was observed due to
the increased variability in sample morphology of the regular carrier.
8
Scanning electron microscopy (SEM) Ra ¼ 1l
R l
0 jzðxÞ  dx Particles produced at large scale exhibited changes not only in surface roughness but also in shape at varying
outlet temperatures. A decrease in surface roughness led to a lower FPF.
29
Confocal laser scanning microscope
(CLSM)
— The obtained roughness proﬁles were consistent with results of SEM image analysis and showed distinct
trends. In general, rough particles obtained at low outlet temperatures were spherical, whereas higher
drying temperatures resulted in particles with multiple surface indentations and smoother surface. Different
roughness was a result of underlying crystallization processes.
15,82,83
Particle image analysis Roughness¼ PerimeterConvexPerim All crystallized particles had rougher surfaces than the commercial lactose, leading to improved drug
aerosolization performance due to lower drug–carrier adhesion forces.
70
Indirect method Colloid probe microscopy — Median force (F0.5) value was chosen as the best descriptor of drug–carrier adhesion force. The values for
polymer coated/uncoated carriers followed a rank order of PVP coated 4un-coated 4EC coated lactose,
which showed an opposite trend of FPF.
86,89,90
Air depression sieving — It was considered as a simple method to evaluate drug–carrier adhesion force, based on the aspiration
principle that the whole blend used in DPI was taken into account. The detailed procedure was presented
by Le et al.91. Greater drug–carrier adhesion force was obtained under higher humidity, leading to
decreased FPF. Kaialy et al.7 also used this method to evaluate the adhesion force between salbutamol
sulphate and different lactose grades in the same size range, demonstrating that lactose particles with more
elongated/irregular shape, and rougher surface were preferred to improve FPF.
7,91
ConvexPerim, circumscribed particle perimeter;
l, length;
N, the number of data points in a topographical proﬁle;
Perimeter, estimated particle perimeter;
Ra, the mean Ra values of several line proﬁles over the analyzed surface;
RRMS, surface root mean square roughness;
yi, the distance of asperities (i) from the center line;
Z, the deviation of all points from a plane ﬁt to the test surface over sampling length l;
—, no equation was reported for the method.
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Tingting Peng et al.316Neither rugosity nor Fshape can distinguish the surface smoothness
of two particles if they differ substantially in macroscopic shape.
Therefore, in order to accurately compare the surface smoothness
of particles with different ER values, a new shape descriptor, Srec,
was introduced by Zeng et al.28. Srec is a factor that assumes a
rectangular shape and takes both Fshape and ER into consideration.5.3. Surface roughness
For efﬁcient delivery of drug deep into the lung, drug particles
need to be efﬁciently loaded onto and liberated from the carrier,
processes which are largely dependent on characteristics of the
contact area. Most pharmaceutical grade carriers for use in DPIs
have particles with a certain amount of surface roughness67 which
can be categorized into three groups (Fig. 7)78. First, carrier
particles of micrometer topography generally have a large contact
area for micronized drugs to adhere to, resulting in strong
interaction and poor aerosol efﬁciency. Additionally, entrapment
of drug in the cavities or valleys of the carrier surface may further
reduce drug–carrier detachment. Secondly, carrier particles of
nanometer topography can provide binding sites for drugs which
are favorable for drug detachment from the carrier surface after
inhalation thus contributing to higher FPF values7. Thirdly, carrier
particles with smooth surfaces also have a large contact area for
drug attachment leading to poor drug–carrier detachment. There-
fore, only carrier surface irregularity of a certain scale, namely
nanometer topography, provides a sufﬁciently low total contact
area for drug to bind with weak adhesive forces78. Particles with
large surface irregularity (micrometer topography) or irregularity
approaching zero (smooth) bind drug with strong adhesive force.
Reports about the inﬂuence of surface roughness on aerosoliza-
tion performance of a DPI are contradictory. For example, Kaialy
et al.7,79 found that rougher lactose particles showed a smaller
adhesion force with salbutamol sulphate and produced enhanced
DPI performance. In contrast, Flament et al.80 found a linear
relationship between lactose roughness and FPF, the rougher the
lactose surface the greater the adherence of terbutaline sulphate
and the lower the FPF. This linear relationship can be explained as
due to an increase in contact points between drug and carrier as
surface roughness increases. This stabilizes the blend but leads to
less drug deaggregation from carrier when the blend is carried by
an airﬂow. Since particle size and shape also inﬂuence interparti-
culate forces, study of the inﬂuence of carrier surface properties on
aerosol performance of a DPI becomes even more difﬁcult. In one
study, glass beads with different surface roughness but the same
size and shape were used as model carriers to investigate the
relationship81. The surface-modiﬁed glass beads were produced in
a ball mill using different grinding materials and grinding times
followed by plasma etching. The results indicate that the greater
the surface roughness the higher the FPF.
These conﬂicting ﬁndings reveal that, in order to increase FPF,
an optimum level of surface roughness is needed. They also
suggest that modifying surface morphological properties is an
effective way to alter particle interactions and improve aerosol
performance. To date, various techniques have been employed to
modify the surface roughness of carriers in order to achieve a high
FPF value. These include mechanical milling11, spray drying82,83,
freeze drying47, anti-solvent precipitation from different media and
under different crystallization conditions31,84, polymer coating via
spray drying85, dry mechano-fusion29, adding ﬁne particles to ﬁll
in carrier “active sites”23,59, and adding agents such as leucine86,magnesium stearate87, and polaxamer88 to reduce surface passiva-
tion of high surface free energy sites.
Since surface roughness is closely related to surface energy and the
adhesion force between drug and carrier, its assessment using direct
and indirect methods is very important (Table 27,8,15,29,70,82,83,86,89–91).
Atomic force microscopy (AFM), SEM, confocal laser scanning
microscopy (CLSM) and particle image analysis can directly provide
data related to surface roughness. The drug–carrier adhesion force can
also be measured by colloid probe microscopy and air jet sieving.6. Conclusions
Carrier physical properties, such as particle size, morphology, and
surface roughness, play signiﬁcant roles in determining DPI perfor-
mance since they directly inﬂuence the adhesion and detachment of
drug and carrier. Studies of the effects of these properties on drug
aerosolization efﬁciency have given controversial results for two main
reasons. First, a complete understanding of the independent inﬂuence
of each property remains challenging as the properties are interdepen-
dent. Secondly, most studies have focused on one property and given
less attention to others. Despite these limitations, it is clear that higher
drug deposition is achieved by reducing the adhesion force of drug
and carrier in mixed DPI formulations.Acknowledgements
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